These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25278187)

  • 1. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
    Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
    Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
    Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
    Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
    J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells.
    Gao C; Leyton JV; Schimmer AD; Minden M; Reilly RM
    Appl Radiat Isot; 2016 Apr; 110():1-7. PubMed ID: 26748017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates.
    Zereshkian A; Leyton JV; Cai Z; Bergstrom D; Weinfeld M; Reilly RM
    Nucl Med Biol; 2014; 41(5):377-83. PubMed ID: 24637100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A radiolabeled antibody targeting CD123(+) leukemia stem cells - initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML.
    Leyton JV; Gao C; Williams B; Keating A; Minden M; Reilly RM
    Leuk Res Rep; 2015; 4(2):55-9. PubMed ID: 26500848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
    J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
    Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
    Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Cadherin and Tie2 positive CD34⁺CD38⁻CD123⁺ leukemic stem cell populations can develop acute myeloid leukemia more effectively in NOD/SCID mice.
    Qiu S; Jia Y; Xing H; Yu T; Yu J; Yu P; Tang K; Tian Z; Wang H; Mi Y; Rao Q; Wang M; Wang J
    Leuk Res; 2014 May; 38(5):632-7. PubMed ID: 24703771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.
    Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F
    Int J Cancer; 2008 Nov; 123(9):2222-7. PubMed ID: 18688847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
    Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
    Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
    Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
    Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
    He SZ; Busfield S; Ritchie DS; Hertzberg MS; Durrant S; Lewis ID; Marlton P; McLachlan AJ; Kerridge I; Bradstock KF; Kennedy G; Boyd AW; Yeadon TM; Lopez AF; Ramshaw HS; Iland H; Bamford S; Barnden M; DeWitte M; Basser R; Roberts AW
    Leuk Lymphoma; 2015 May; 56(5):1406-15. PubMed ID: 25248882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
    Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
    J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ImmunoPET, [
    Srideshikan SM; Brooks J; Zuro D; Kumar B; Sanchez J; Echavarria Parra L; Orellana M; Vishwasrao P; Nair I; Chea J; Poku K; Bowles N; Miller A; Ebner T; Molnar J; Rosenthal J; Vallera DA; Wong JYC; Stein AS; Colcher D; Shively JE; Yazaki PJ; Hui SK
    Clin Cancer Res; 2019 Dec; 25(24):7463-7474. PubMed ID: 31548348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice.
    Ailles LE; Gerhard B; Kawagoe H; Hogge DE
    Blood; 1999 Sep; 94(5):1761-72. PubMed ID: 10477702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.